Early G1 cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4513-4522

  Ismail, Amin ^a   Bandla, Santhoshi ^a   Reveiller, Marie ^a   Toia, Liana ^a   Zhou, Zhongren ^a   Gooding, William E ^b   Kalatskaya, Irina ^d   Stein, Lincoln ^d   D'Souza, Mary ^a   Litle, Virginia R ^a   Peters, Jeffrey H ^a   Pennathur, Arjun ^c   Luketich, James D ^c   Godfrey, Tony E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AKAP9 GENE; AMPLICON; ANKIB1 GENE; ARTICLE; C7ORF64 GENE; CALCR GENE; CANCER SURVIVAL; CCDC132 GENE; CDK4 GENE; CDK6 GENE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMOSOME 7Q; CHROMOSOME 7Q21; COHORT ANALYSIS; CONTROLLED STUDY; CYP51A1 GENE; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; FAM133B GENE; GATAD1 GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; HEPACAM2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KRIT1 GENE; LOC401387 GENE; MAJOR CLINICAL STUDY; MGC16142 GENE; MTERF GENE; ONCOGENE; OVERALL SURVIVAL; PEX1 GENE; PRIORITY JOURNAL; SAMD9 GENE; SAMD9L GENE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; ADULT; AGED; CHROMOSOME 7; COPY NUMBER VARIATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO( 2,3-D)PYRIMIDIN-7-ONE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 7; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DNA COPY NUMBER VARIATIONS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960334239     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0244     Document Type: Article

References (44)

1. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006;13:12-30. (Pubitemid 43117641)
2. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070-4. (Pubitemid 38961957)
3. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8. (Pubitemid 32695034)
4. Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006;202:588-96; discussion 96-8.
5. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49. (Pubitemid 28515376)
6. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9. (Pubitemid 44967957)
7. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
8. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Steinhoff M, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-9. (Pubitemid 46108313)
9. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Genomewide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 2010;3:1176-86.
10. van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ, et al. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet 2009;189:37-42.
11. van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, Rosenberg C, et al. Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 2006;166:157-62.
12. van Dekken H, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, et al. Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer 2008;47:649-56. (Pubitemid 351847578)
13. Ismail A, Bateman A. Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett 2009;278:230-40.
14. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
15. Boylan JF, Sharp DM, Leffet L, Bowers A, Pan W. Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression. Exp Cell Res 1999;248:110-4. (Pubitemid 29393934)
16. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
17. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
18. Korkola J, Gray JW. Breast cancer genomes - form and function. Curr Opin Genet Dev 2010;20:4-14.
19. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010;107:163-224.
20. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-52. (Pubitemid 32448320)
21. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304. (Pubitemid 47057800)
22. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-26.
23. Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 2010;11:1000-17.
24. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010;46:1260-70.
25. Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Drexler HG, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008;22:387-92. (Pubitemid 351250544)
26. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-4. (Pubitemid 27152546)
27. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62. (Pubitemid 46211532)
28. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41. (Pubitemid 41540083)
29. Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003;5:5-18.
30. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95. (Pubitemid 32204552)
31. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004;9:95-104. (Pubitemid 39137499)
32. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010;116:2621-34.
33. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75. (Pubitemid 44572384)
34. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995;26:35-9.
35. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 2010;9:1809-18.
36. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009;69:4443-53.
37. Lucas JJ, Domenico J, Gelfand EW. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells. Mol Cancer Res 2004;2:105-14. (Pubitemid 38250427)
38. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493-504. (Pubitemid 39485668)
39. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009;28:2925-39.
40. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Grana X, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010;138:1920-30.
41. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
42. + disease. Breast Cancer Res 2009;11:112.
43. Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, et al. Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 2005;312:206-13. (Pubitemid 40096470)
44. Coley HM, Shotton CF, Kokkinos MI, Thomas H. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Gynecol Oncol 2007;105:462-9. (Pubitemid 46591975)